MX2022015567A - Productos terapeuticos contra el cancer de inhibidores selectivos de cdk4/6. - Google Patents
Productos terapeuticos contra el cancer de inhibidores selectivos de cdk4/6.Info
- Publication number
- MX2022015567A MX2022015567A MX2022015567A MX2022015567A MX2022015567A MX 2022015567 A MX2022015567 A MX 2022015567A MX 2022015567 A MX2022015567 A MX 2022015567A MX 2022015567 A MX2022015567 A MX 2022015567A MX 2022015567 A MX2022015567 A MX 2022015567A
- Authority
- MX
- Mexico
- Prior art keywords
- compounds
- cancer therapeutics
- cancer
- selective cdk4
- inhibitor cancer
- Prior art date
Links
- 229940124297 CDK 4/6 inhibitor Drugs 0.000 title abstract 2
- 239000012830 cancer therapeutic Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 229940124650 anti-cancer therapies Drugs 0.000 abstract 1
- 238000011319 anticancer therapy Methods 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 230000005907 cancer growth Effects 0.000 abstract 1
- 125000005313 fatty acid group Chemical group 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 230000003389 potentiating effect Effects 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- -1 pyridinylpiperazine-pyrrolopyrimidine compounds Chemical class 0.000 abstract 1
- 238000011282 treatment Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/20—Spiro-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Esta descripción expone modalidades de inhibidores de CDK 4/6 selectivos y potentes que muestran una inhibición ventajosa del crecimiento del cáncer, incluso en concentraciones bajas. Como se describe en este documento, los compuestos del presente planteamiento comprenden compuestos de piridinilpiperazina sustituida-pirrolopirimidina que tienen una porción de ácido graso. Los compuestos descritos en este documento se pueden usar como compuestos farmacéuticos para terapias anticancerosas y son útiles para el tratamiento, prevención y/o paliación del cáncer. Fórmula (a) (ver Fórmula).
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063037898P | 2020-06-11 | 2020-06-11 | |
| PCT/IB2021/055124 WO2021250614A1 (en) | 2020-06-11 | 2021-06-10 | Selective cdk4/6 inhibitor cancer therapeutics |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022015567A true MX2022015567A (es) | 2023-01-19 |
Family
ID=78847036
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022015567A MX2022015567A (es) | 2020-06-11 | 2021-06-10 | Productos terapeuticos contra el cancer de inhibidores selectivos de cdk4/6. |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US11964983B2 (es) |
| EP (1) | EP4165046A1 (es) |
| JP (1) | JP2023530096A (es) |
| KR (1) | KR20230023661A (es) |
| CN (1) | CN115698015A (es) |
| AU (1) | AU2021287380A1 (es) |
| BR (1) | BR112022024484A2 (es) |
| CA (1) | CA3185467A1 (es) |
| IL (1) | IL298568A (es) |
| MX (1) | MX2022015567A (es) |
| WO (1) | WO2021250614A1 (es) |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9527857B2 (en) | 2013-03-15 | 2016-12-27 | GI Therapeutics, Inc. | HSPC-sparing treatments for RB-positive abnormal cellular proliferation |
| WO2014144740A2 (en) * | 2013-03-15 | 2014-09-18 | G1 Therapeutics, Inc. | Highly active anti-neoplastic and anti-proliferative agents |
| WO2018005863A1 (en) * | 2016-07-01 | 2018-01-04 | G1 Therapeutics, Inc. | Pyrimidine-based compounds for the treatment of cancer |
| AU2017370694A1 (en) | 2016-12-08 | 2019-07-25 | Icahn School Of Medicine At Mount Sinai | Compositions and methods for treating CDK4/6-mediated cancer |
| CN112839646A (zh) * | 2018-08-16 | 2021-05-25 | G1治疗公司 | 用于治疗医学疾病的苯并噻吩雌激素受体调节剂 |
-
2021
- 2021-06-10 EP EP21821730.5A patent/EP4165046A1/en active Pending
- 2021-06-10 WO PCT/IB2021/055124 patent/WO2021250614A1/en unknown
- 2021-06-10 CN CN202180039343.7A patent/CN115698015A/zh active Pending
- 2021-06-10 CA CA3185467A patent/CA3185467A1/en active Pending
- 2021-06-10 US US18/008,636 patent/US11964983B2/en active Active
- 2021-06-10 BR BR112022024484A patent/BR112022024484A2/pt unknown
- 2021-06-10 MX MX2022015567A patent/MX2022015567A/es unknown
- 2021-06-10 JP JP2022576082A patent/JP2023530096A/ja active Pending
- 2021-06-10 AU AU2021287380A patent/AU2021287380A1/en active Pending
- 2021-06-10 KR KR1020227044245A patent/KR20230023661A/ko unknown
- 2021-06-10 IL IL298568A patent/IL298568A/en unknown
-
2023
- 2023-12-15 US US18/541,733 patent/US20240116942A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US11964983B2 (en) | 2024-04-23 |
| KR20230023661A (ko) | 2023-02-17 |
| EP4165046A1 (en) | 2023-04-19 |
| IL298568A (en) | 2023-01-01 |
| US20230227461A1 (en) | 2023-07-20 |
| CA3185467A1 (en) | 2021-12-16 |
| WO2021250614A1 (en) | 2021-12-16 |
| AU2021287380A1 (en) | 2023-01-05 |
| JP2023530096A (ja) | 2023-07-13 |
| CN115698015A (zh) | 2023-02-03 |
| BR112022024484A2 (pt) | 2022-12-27 |
| US20240116942A1 (en) | 2024-04-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112018070677A2 (pt) | inibidores de mcl-1 macrocíclicos para o tratamento de câncer | |
| TW200613306A (en) | Imidazotriazines as protein kinase inhibitors | |
| UA95955C2 (ru) | Ингибиторы обратной транскриптазы вич | |
| EA201691401A1 (ru) | Индазольные соединения в качестве ингибиторов irak4 | |
| AU2020281332A8 (en) | Dna-dependent protein kinase inhibitor | |
| EA201001618A1 (ru) | Ингибиторы syk протеинкиназ | |
| YU84603A (sh) | Novi inhibitori tirozin kinaze | |
| SG132683A1 (en) | Imidazopyrazine tyrosine kinase inhibitors | |
| MX2016016530A (es) | Inhibidores de fosfatidilinositol 3-quinasa. | |
| MX2009005201A (es) | Derivados de estratrieno sustituidos como inhibidores de 17beta hsd. | |
| SA519402103B1 (ar) | 1,6-naphthyridine مشتقات 1، 6 نفثيرايدين CDK4/6 على شكل مثبط | |
| BRPI0809542A8 (pt) | Compostos derivados de indol tendo atividade de inibição de cpla2, composição farmacêutica, e métodos de produção dos referidos compostos | |
| MX2023006145A (es) | Inhibidores de prmt5 novedosos. | |
| MX2022009059A (es) | Compuestos heterociclicos novedosos utiles como inhibidores selectivos de aurora a. | |
| MX2022013401A (es) | Compuestos de azalactama como inhibidores de hpk1. | |
| AU2022367432A1 (en) | Quinoline compounds as inhibitors of kras | |
| CR20210364A (es) | Compuestos de quinolina como inhibidores de quinasas tam y met | |
| MX2021002878A (es) | Inhibidores de cd73 y usos farmaceuticos de los mismos. | |
| CR20220667A (es) | Derivados de tetrazol como inhibidores de trpa1 | |
| CR20220139A (es) | Inhibidor de diacilglicerol aciltransferasa 2 | |
| MX2022015567A (es) | Productos terapeuticos contra el cancer de inhibidores selectivos de cdk4/6. | |
| MX2022007488A (es) | Agentes terapeuticos selectivos contra el cancer inhibidores de cdk4/6. | |
| ZA202207449B (en) | Selective cdk4/6 inhibitor cancer therapeutics | |
| MX2021010295A (es) | Nuevo inhibidor de cinasa pan-proteina de fibrosarcoma rapidamente acelerado (raf) y su uso. | |
| AU2022350571A1 (en) | Fgfr inhibitors and methods of use thereof |